These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 10618007)

  • 21. Neurobehavioral and neuropsychiatric symptoms in Alzheimer's disease: characteristics and treatment.
    Chung JA; Cummings JL
    Neurol Clin; 2000 Nov; 18(4):829-46. PubMed ID: 11072263
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Rivastigmine: a review of its clinical effectiveness].
    Spiegel R
    Rev Neurol; 2002 Nov 1-15; 35(9):859-69. PubMed ID: 12436385
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Behavioral effects of current Alzheimer's disease treatments: a descriptive review.
    Cummings JL; Mackell J; Kaufer D
    Alzheimers Dement; 2008 Jan; 4(1):49-60. PubMed ID: 18631950
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Changes in neuropsychiatric symptoms as outcome measures in clinical trials with cholinergic therapies for Alzheimer disease.
    Cummings JL
    Alzheimer Dis Assoc Disord; 1997; 11 Suppl 4():S1-9. PubMed ID: 9339266
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The cholinergic system in the pathophysiology and treatment of Alzheimer's disease.
    Hampel H; Mesulam MM; Cuello AC; Farlow MR; Giacobini E; Grossberg GT; Khachaturian AS; Vergallo A; Cavedo E; Snyder PJ; Khachaturian ZS
    Brain; 2018 Jul; 141(7):1917-1933. PubMed ID: 29850777
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Advances in the pharmacotherapy of Alzheimer's disease.
    Gauthier S
    CMAJ; 2002 Mar; 166(5):616-23. PubMed ID: 11898943
    [No Abstract]   [Full Text] [Related]  

  • 27. A review on cholinesterase inhibitors for Alzheimer's disease.
    Anand P; Singh B
    Arch Pharm Res; 2013 Apr; 36(4):375-99. PubMed ID: 23435942
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reimagining cholinergic therapy for Alzheimer's disease.
    Giacobini E; Cuello AC; Fisher A
    Brain; 2022 Jul; 145(7):2250-2275. PubMed ID: 35289363
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neurochemical basis for symptomatic treatment of Alzheimer's disease.
    Francis PT; Ramírez MJ; Lai MK
    Neuropharmacology; 2010; 59(4-5):221-9. PubMed ID: 20156462
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of vascular dementia-evidence from clinical trials with cholinesterase inhibitors.
    Erkinjuntti T; Román G; Gauthier S
    Neurol Res; 2004 Jul; 26(5):603-5. PubMed ID: 15265282
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New therapeutic approaches to Alzheimer's disease.
    Schneider LS
    J Clin Psychiatry; 1996; 57 Suppl 14():30-6. PubMed ID: 9024334
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cholinergic therapy for neuropsychiatric symptoms in neurologic disorders.
    Kaufer DI
    Curr Psychiatry Rep; 1999 Oct; 1(1):78-84. PubMed ID: 11122908
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cholinergically mediated augmentation of cerebral perfusion in Alzheimer's disease and related cognitive disorders: the cholinergic-vascular hypothesis.
    Claassen JA; Jansen RW
    J Gerontol A Biol Sci Med Sci; 2006 Mar; 61(3):267-71. PubMed ID: 16567376
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacological treatment of neuropsychiatric symptoms in Alzheimer's disease: a systematic review and meta-analysis.
    Wang J; Yu JT; Wang HF; Meng XF; Wang C; Tan CC; Tan L
    J Neurol Neurosurg Psychiatry; 2015 Jan; 86(1):101-9. PubMed ID: 24876182
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of Alzheimer's disease.
    Cummings JL
    Clin Cornerstone; 2001; 3(4):27-39. PubMed ID: 11432120
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Is there a rationale for the use of acetylcholinesterase inhibitors in the therapy of Alzheimer's disease?
    Benzi G; Moretti A
    Eur J Pharmacol; 1998 Apr; 346(1):1-13. PubMed ID: 9617746
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacological aspects of the acetylcholinesterase inhibitor galantamine.
    Ago Y; Koda K; Takuma K; Matsuda T
    J Pharmacol Sci; 2011; 116(1):6-17. PubMed ID: 21498956
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cholinesterase inhibitors proposed for treating dementia in Alzheimer's disease: selectivity toward human brain acetylcholinesterase compared with butyrylcholinesterase.
    Pacheco G; Palacios-Esquivel R; Moss DE
    J Pharmacol Exp Ther; 1995 Aug; 274(2):767-70. PubMed ID: 7636741
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acetylcholinesterase inhibitors: novel activities of old molecules.
    Racchi M; Mazzucchelli M; Porrello E; Lanni C; Govoni S
    Pharmacol Res; 2004 Oct; 50(4):441-51. PubMed ID: 15304241
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cholinergic strategies in the treatment of Alzheimer's disease.
    Davidson M; Stern RG; Bierer LM; Horvath TB; Zemishlani Z; Markofsky R; Mohs RC
    Acta Psychiatr Scand Suppl; 1991; 366():47-51. PubMed ID: 1897375
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.